References
- 1Webster R, Salam A, de Silva HA, Selak V, Stepien S, Rajapakse S, et al. Fixed low-dose triple combination antihypertensive medication vs usual care for blood pressure control in patients with mild to moderate hypertension in Sri Lanka: A randomized clinical trial. JAMA. 2018;320:566–79. DOI: 10.1001/jama.2018.10359
- 2Rodgers A, Salam A, Cushman W, Silva A de, Tanna GLD, Gnanenthiran SR, et al. Rationale for a new low-dose triple single pill combination for the treatment of hypertension. Glob Heart. 2024;19. DOI: 10.5334/gh.1283
- 3Rodgers A, Salam A, Schutte AE, Cushman WC, De Silva HA, Di Tanna GL, et al. Efficacy and safety of a novel low-dose triple single-pill combination compared with placebo for initial treatment of hypertension. J Am Coll Cardiol. 2024;84:2393–2403. DOI: 10.1016/j.jacc.2024.08.025
- 4Rodgers A, Salam A, Schutte AE, Cushman WC, De Silva HA, Di Tanna GL, et al. Efficacy and safety of a novel low-dose triple single-pill combination of telmisartan, amlodipine and indapamide, compared with dual combinations for treatment of hypertension: a randomised, double-blind, active-controlled, international clinical trial. The Lancet. 2024;404:1536–1546. DOI: 10.1016/S0140-6736(24)01744-6
- 5Rahimi K, Bidel Z, Nazarzadeh M, Copland E, Canoy D, Ramakrishnan R, et al. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. The Lancet. 2021;397:1625–1636. DOI: 10.1016/S0140-6736(21)00590-0
- 6Lasserson DS, Buclin T, Glasziou P. How quickly should we titrate antihypertensive medication? Systematic review modelling blood pressure response from trial data. Heart Br Card Soc. 2011;97:1771–1775. DOI: 10.1136/hrt.2010.221473
- 7Muntner P, Shimbo D, Carey RM, Charleston JB, Gaillard T, Misra S, et al. Measurement of blood pressure in humans: A scientific statement from the American Heart Association. Hypertens Dallas Tex 1979. 2019;73:e35–e66. DOI: 10.1161/HYP.0000000000000087
- 8Volpe M, de la Sierra A, Ammentorp B, Laeis P. Open-label study assessing the long-term efficacy and safety of triple olmesartan/amlodipine/hydrochlorothiazide combination therapy for hypertension. Adv Ther. 2014;31:561–574. DOI: 10.1007/s12325-014-0117-9
- 9Ábrahám G, Dézsi CA. The antihypertensive efficacy of the triple fixed combination of perindopril, indapamide, and amlodipine: The results of the PETRA study. Adv Ther. 2017;34:1753–1763. DOI: 10.1007/s12325-017-0572-1
- 10Páll D, Szántó I, Szabó Z. Triple combination therapy in hypertension: The antihypertensive efficacy of treatment with perindopril, amlodipine, and indapamide SR. Clin Drug Investig. 2014;34:701–708. DOI: 10.1007/s40261-014-0223-0
- 11Tóth K, PIANIST Investigators. Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients). Am J Cardiovasc Drugs Drugs Devices Interv. 2014;14:137–145. DOI: 10.1007/s40256-014-0067-2
- 12Stroppa C, Hunjan I, Umulisa A, Irebe B, Parati G, Bianchetti MG, et al. Single-pill, triple antihypertensive therapy in rural sub-Saharan Africa: Preliminary experience. Cardiol Ther. 2024;13:431–442. DOI: 10.1007/s40119-024-00358-5